Accelerating Advanced Therapy Treatments with the FDA’s RMAT Designation Phacilitate interview

Accelerating Advanced Therapy Treatments with the FDA’s RMAT Designation

An introduction to the FDA’s RMAT designation with Dr Julie Allickson, Director, Regenerative Medicine Clinical Center at Wake Forest Institute for Regenerative Medicine

The FDA introduced the ‘Regenerative Medicine Advanced Therapy Designation’ as part of the USA’s 21st Century Cures act of 2016, with the aim of accelerating product approvals.
 
So, what is the FDA’s definition of regenerative medicine and what are the criteria for applying for an RMAT designation?
 
Dr Julie Allickson from the Regenerative Medicine Clinical Center at Wake Forest Institute for Regenerative Medicine gives her take on the new pathway and its criteria plus an overview of what we know about the applications and approvals so far in this two-minute video